Moderna, Inc. Common Stock — Quarterly Financial Statements (NASDAQ:MRNA)

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Market Capitalization 57 B
Employee 4 700
Founded N/A
CEO Stéphane Bancel
Website www.modernatx.com
Headquarter Delaware, United States
FIGI BBG003PHHZT1
Industry Biotechnology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

Price to earnings ratio

-8.78

Price to sales ratio

12.29

Related tickers

#	Name	Price	24h %	7d %	1M %	1Y %	Market Cap
205	REGN Regeneron Pharmaceuticals, Inc. - Common Stock	807.71 USD	-0.87%	-2.58%	+15.49%	+39.95%	83.16 B USD
259	ARGX argenx SE - American Depositary Shares	1058.90 USD	+1.13%	+2.43%	+21.11%	+50.13%	65.53 B USD
339	RVMD Revolution Medicines, Inc. - Common Stock	221.15 USD	+2.65%	+4.55%	+20.07%	+299.19%	47.40 B USD
444	ALNY Alnylam Pharmaceuticals, Inc. - Common Stock	236.56 USD	-1.02%	+3.36%	-17.82%	-47.73%	31.65 B USD

Frequently asked questions about Moderna, Inc. Common Stock

What is the Moderna, Inc. Common Stock stock price today?

The current price of Moderna, Inc. Common Stock (MRNA) is 142.77. Over the past 24 hours, the stock has changed by -4.60%. Follow the MRNA chart for real-time price dynamics.

What is the stock ticker of Moderna, Inc. Common Stock?

Moderna, Inc. Common Stock trades under the ticker MRNA. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Moderna, Inc. Common Stock stock going up?

MRNA has changed by +7.75% over the last week, +159.39% over the last month, and +488.50% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Moderna, Inc. Common Stock?

Moderna, Inc. Common Stock currently has a market capitalization of 57 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Moderna, Inc. Common Stock earnings last quarter?

Last quarter, Moderna, Inc. Common Stock reported earnings of -1.97 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Moderna, Inc. Common Stock revenue for the last quarter?

Moderna, Inc. Common Stock reported quarterly revenue of 145 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Moderna, Inc. Common Stock net income for the last quarter?

Moderna, Inc. Common Stock reported net income of -782 M for the last quarter. The previous quarter showed -1.34 B, which means net income changed by +41.77%.

How many employees does Moderna, Inc. Common Stock have?

As of the latest available data, Moderna, Inc. Common Stock has 4 700 employees. Workforce size can provide additional context about the company's scale and operations.

What is Moderna, Inc. Common Stock EBITDA?

Moderna, Inc. Common Stock EBITDA is -759 M, and its EBITDA margin is -523.45%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Moderna, Inc. Common Stock stock?

You can buy Moderna, Inc. Common Stock (MRNA) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Moderna, Inc. Common Stock stock?

Investing in Moderna, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the MRNA chart and related analysis on metatrader.com as part of your research.

Moderna, Inc. - Common Stock

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.